A number of filgrastim and epoetin alfa biosimilars are available to European oncologists, and since 2015, U.S. oncologists have had access to Zarxio—the first biosimilar launched in the United States. Across both regions, oncologists have widely reported they have prescribed biosimilars, and with an increasing number of biosimilars submitted for approval, alongside pressures from payers and institutions to lower costs, the use of biosimilars is likely to increase. The absence of ESA biosimilars in the United States and of monoclonal antibody biosimilars for oncology across both regions presents opportunities for biosimilar manufacturers as well as considerations for companies wishing to defend against biosimilar erosion. We conducted market research with medical oncologists and hematology-oncologists in France, Germany, and the United States to gain insights on attitudes toward biosimilars, drivers and barriers to biosimilar use, and expectations for future adoption.

Related Reports

Biosimilars - Emerging Biosimilars - Special Topics: Oncology Biosimilars In The United States - Wave 1

Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the seco...

View Details

Oncology Clinical Trial Monitor - Clinical Trials - Oncology Clinical Trial Monitor

Oncology Clinical Trial Monitor is a continuously updated dashboard, highlighting the global immuno-oncology clinical development landscape and clinical outcomes for key standards of care. This dyn...

View Details

Biosimilars - Market Events And Forecast - Oncology

In 2018, sales of branded monoclonal antibody biologics in oncology exceeded $20 billion across the major markets (United States, EU5, and Jap...

View Details

Biomarkers In Oncology - Access & Reimbursement - Detailed, Expanded Analysis: Multi-indication (US)

Biomarker-driven prescribing is paramount in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small-cell lung cancer and malignant mela...

View Details